KR960704923A - HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS) - Google Patents
HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)Info
- Publication number
- KR960704923A KR960704923A KR1019960701994A KR19960701994A KR960704923A KR 960704923 A KR960704923 A KR 960704923A KR 1019960701994 A KR1019960701994 A KR 1019960701994A KR 19960701994 A KR19960701994 A KR 19960701994A KR 960704923 A KR960704923 A KR 960704923A
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- amino acid
- aids
- acid sequence
- hiv
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 41
- 208000030507 AIDS Diseases 0.000 title claims abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 5
- 230000001939 inductive effect Effects 0.000 title claims abstract 4
- 230000028993 immune response Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims abstract 9
- 239000003814 drug Substances 0.000 claims abstract 5
- 239000012634 fragment Substances 0.000 claims abstract 5
- 230000000069 prophylactic effect Effects 0.000 claims abstract 5
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 11
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 238000003306 harvesting Methods 0.000 claims 2
- 241000024188 Andala Species 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 102000006390 HLA-B Antigens Human genes 0.000 description 3
- 108010058607 HLA-B Antigens Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
HIV의 전체 단백질의 단편으로서, 그 단편이 8~11개의 아미노산의 연속되는 서열을 함유하는 펩티드이고, HLA 결합 모티프에 상당하며, 실제로 HLA에 결합하고, 또한 HIV 감염세포를 표적으로 하는 킬리세포를 유도할 수 있는 펩티드를 개시한다. 이 펩티드는 항 AIDS 예방,치료제로서 유효하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 RMA-S-B*3501 세포상에 있어서의 HLA-B*3501 항원의 발현 레벨의 변화를 나타낸다. 도면중, △은 HLA-B*3501 항원 결합성이 있는 자기항원펩티드 28H(LPGPKFLQY), ○은 37F(LPFDFTPGY), □은 결합성이 없는 펩티드 MP-1(KGIGKVFTLTV)의 첨가에 의한 HLA-B*3501 발현 레벨의 변화를 나타낸다.
제2도는 펩티드로서 HIV(B35)-16을 이용할 때의 특이적 세포독활성을 나타낸다, 도면중, ●은 표지표적 세포가 T2-B*3501 세포일 경우, ○은 표지 표적 세표가 T2 세포일 경우인 콘트롤이다. 펩티드로 자극하여 배양한 환자말초 림프구는 1×105, 2.5×104또는 6.25×103개의 3단계 세포수를 이용하였으나, 도시된 특이적 세포독활성의 값은 1×105개의 세포를 이용했을 때의 것이다.
Claims (17)
- HIV의 전체 단백질의 단편으로서, 그 단편이 8~11개의 아미노산의 연속되는 서열을 함유하는 펩티드이고, HLA 결합 모티프에 상당하며, 실제로 HLA에 결합하고, 또한 HIV 감염세포를 표적으로 하는 킬리세포를 유도할 수 있는 펩티드.
- 제1항에 있어서, 그 펩티드가 9~11개의 아미노산의 연속되는 서열을 갖는 것을 특징으로 하는 펩티드.
- 제1항에 있어서, 그 펩티드가 서열번호 1~63중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
- 제1항에 있어서, HLA 결합 모티프가 8~11개의 아미노산 서열로서, 2번째가 Pro, C 말단이 Tyr, Leu, Ile, Met, Phe 및 Ala로 이루어지는 군에서 선택된 아미노산인 것을 특징으로 하는 펩티드.
- 제4항에 있어서, 그 펩티드가 서열번호 1~24중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
- 제4항에 있어서, 그 펩티드가 서열번호 1~13중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
- 제1항에 있어서, HLA 결합 모티프가 8~11개의 아미노산 서열로서, 2번째가 Pro, Ala 및 Gly로 이루어지는 군에서 선택된 아미노산이고, C말단이 Ile, Leu, Val, Phe 및 Met로 이루어지는 군에서 선택된 아미노산인 것을 특징으로 하는 펩티드.
- 제7항에 있어서, 그 펩티드가 서열번호 25~46중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
- 제1항에 있어서, HLA 결합 모티프가 8~11개의 아미노산 서열로서, 2번째가 Leu, Val, Tyr 및 Phe로 이루어지는 군에서 선택된 아미노산이고, C 말단이 Arg인 것을 특징으로 하는 펩티드.
- 제9항에 있어서, 그 펩티드가 서열번호 47~63중 어느 하나의 아미노산 서열을 갖는 펩티드인 것을 특징으로 하는 펩티드.
- 제1항의 펩티드를 코드하는 것을 특징으로 하는 DNA.
- 제1항의 펩티드 및 의약적으로 허용되는 담체 및/또는 희석제를 함유하는 것을 특징으로 하는 항 AIDS 예방·치료제.
- 제3항의 펩티드 및 의약적으로 허용되는 담체 및/또는 희석제를 함유하는 것을 특징으로 하는 항 AIDS 예방·치료제.
- 제4항의 펩티드 및 의약적으로 허용되는 담체 및/또는 희석제를 함유하는 것을 특징으로 하는 항 AIDS 예방·치료제.
- 제6항의 펩티드 및 의약적으로 허용되는 담체 및/또는 희석제를 함유하는 것을 특징으로 하는 항 AIDS 예방·치료제.
- 제1항의 펩티드를 AIDS환자에 투여함으로써 AIDS를 치료하는 방법.
- HIV의 전체 단백질의 단편으로서, 8~11개의 아미노산의 연속되는 서열을 함유하고, HLA 결합 모티브에 상당하는 펩티드를 합성하고, 합성 펩티드중 실제로 HLA에 결합하는 것을 선택하고, 이어서, 선택한 합성 펩티드중 HLA 클라스 Ⅰ 항원에 결합하여 HIV 질환환자의 말초 림프구를 자극하여 킬러세포를 유도하는 것을 채취하는 것을 특징으로 하는 HIV 감염세포를 표적으로 하는 킬러세포를 유도할 수 있는 펩티드를 채취하는 방법.※ 참고사항: 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP93-261302 | 1993-10-19 | ||
JP26130293 | 1993-10-19 | ||
PCT/JP1994/001756 WO1995011255A1 (fr) | 1993-10-19 | 1994-10-19 | Peptide pouvant induire une reponse immune contre vih et agent contenant ce peptide pour la prevention ou le traitement du sida |
Publications (2)
Publication Number | Publication Date |
---|---|
KR960704923A true KR960704923A (ko) | 1996-10-09 |
KR100235849B1 KR100235849B1 (ko) | 1999-12-15 |
Family
ID=17359912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960701994A KR100235849B1 (ko) | 1993-10-19 | 1994-10-19 | HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS) |
Country Status (8)
Country | Link |
---|---|
US (1) | US5756666A (ko) |
EP (1) | EP0728764A4 (ko) |
JP (1) | JP3814828B2 (ko) |
KR (1) | KR100235849B1 (ko) |
CN (1) | CN1055701C (ko) |
AU (1) | AU685521B2 (ko) |
CA (1) | CA2173138A1 (ko) |
WO (1) | WO1995011255A1 (ko) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US20020168374A1 (en) * | 1992-08-07 | 2002-11-14 | Ralph T. Kubo | Hla binding peptides and their uses |
ATE290592T1 (de) | 1993-11-04 | 2005-03-15 | Innogenetics Nv | Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis |
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
BR9708161A (pt) * | 1996-03-11 | 1999-07-27 | Epimmune Inc | Peptídeos com aumentada afinidade de ligação para moléculas hla |
US6734287B1 (en) | 1998-04-09 | 2004-05-11 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
EP0955311A3 (en) * | 1998-04-09 | 2000-08-16 | Idexx Laboratories, Inc. | Peptide vaccine for canine allergy |
US6667037B1 (en) * | 1998-10-09 | 2003-12-23 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof |
WO2000023053A2 (en) | 1998-10-20 | 2000-04-27 | Salvatore Albani | Artificial antigen-specific cells and related methods |
US6787154B2 (en) * | 1998-10-20 | 2004-09-07 | Salvatore Albani | Artificial antigen presenting cells |
US7807377B2 (en) | 1998-10-20 | 2010-10-05 | Salvatore Albani | Method of isolating antigen-specific T cells employing artificial antigen presenting cells |
NO311807B1 (no) * | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
CA2329152A1 (en) * | 1999-03-30 | 2000-10-05 | Idexx Laboratories, Inc. | Peptide vaccine for canine allergy |
AU757334B2 (en) * | 1999-03-30 | 2003-02-13 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
WO2000073465A1 (fr) * | 1999-05-28 | 2000-12-07 | Ajinomoto Co.,Inc. | Peptides capables d'induire des cellules tueuses specifiques du vih et agents prophylactiques/medicaments contre le vih contenant ces peptides |
FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
CA2386499A1 (en) * | 1999-10-05 | 2001-04-12 | Epimmune, Inc. | Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions |
EP1313505A4 (en) * | 2000-09-01 | 2005-10-12 | Epimmune Inc | HLA BINDING PEPTIDES AND THEIR USES (18.03.02) |
AU2003299134A1 (en) * | 2002-05-20 | 2004-04-23 | The General Hospital Corporation | Cytotoxic t-cell epitopes of hiv-1 virus |
WO2004024129A1 (en) * | 2002-09-10 | 2004-03-25 | Samir Chachoua | Induced remission therapy |
AU2003301012A1 (en) * | 2002-12-13 | 2004-07-09 | Case Western Reserve University | Use of beta-defensins for treating hiv infections |
US7442375B2 (en) * | 2002-12-13 | 2008-10-28 | Case Western Reserve University | Compositions of beta-defensin inducing agents |
US20060147997A1 (en) * | 2004-11-30 | 2006-07-06 | Virosys Pharmaceuticals, Inc. | PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases |
UA97800C2 (uk) | 2006-03-10 | 2012-03-26 | Пептселл Лімітед | Пептидні послідовності і композиції |
JP2010516772A (ja) * | 2007-01-26 | 2010-05-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド | 免疫機能を調節する方法 |
CA2703585A1 (en) | 2007-10-23 | 2009-04-30 | The Regents Of The University Of Colorado | Competitive inhibitors of invariant chain expression and/or ectopic clip binding |
WO2010008554A2 (en) | 2008-07-14 | 2010-01-21 | The Regents Of The University Of Colorado | Methods and products for treating proliferative diseases |
US20100034839A1 (en) * | 2008-07-25 | 2010-02-11 | Martha Karen Newell | Methods for treating viral disorders |
US20100166782A1 (en) * | 2008-07-25 | 2010-07-01 | Martha Karen Newell | Clip inhibitors and methods of modulating immune function |
EP2323680A4 (en) * | 2008-07-25 | 2013-05-01 | Viral Genetics Inc | PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES |
WO2011064779A2 (en) | 2009-11-29 | 2011-06-03 | Yeda Research And Development Co. Ltd. | PEPTIDES DERIVED FROM HIV-1 gp41 TRANSMEMBRANE DOMAIN AND METHODS OF USE THEREOF |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
WO2014026033A1 (en) * | 2012-08-08 | 2014-02-13 | University Of Florida Research Foundation, Inc. | Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
JP2018528974A (ja) * | 2015-09-25 | 2018-10-04 | フロリダ大学 リサーチファウンデーション インコーポレイティッド | ヒトおよびネコにおけるワクチンのためのhiv、sivおよびfivの交差反応性t細胞エピトープ |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS256960B1 (en) * | 1985-11-16 | 1988-04-15 | Viktor Krchnak | Peptides with properties of antigenic determinants and method of their production |
JP3011939B2 (ja) * | 1987-03-02 | 2000-02-21 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 組換えミコバクテリア・ワクチン |
US5128319A (en) * | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
EP0330359A3 (en) * | 1988-02-25 | 1991-06-05 | Bio-Rad Laboratories, Inc. | Composition useful in the diagnosis and treating of hiv-1 infection |
US4943628A (en) * | 1988-06-13 | 1990-07-24 | Ortho Pharmaceutical Corporation | HIV peptide-inducted T cell stimulation |
GB8918200D0 (en) * | 1989-08-09 | 1989-09-20 | Medical Res Council | The peptide fragments of hiv |
EP0510054A1 (en) * | 1990-01-05 | 1992-10-28 | United Biomedical, Inc. | Hiv-1 core protein fragments |
EP0968721A3 (en) * | 1991-12-02 | 2004-02-04 | The Board Of Regents, The University Of Texas System | Use of a composition comprising a peptide for the inhibition of HIV |
CA2157510A1 (en) * | 1993-03-05 | 1994-09-15 | Howard M. Grey | Hla-a2.1 binding peptides and their uses |
DE69430315T2 (de) * | 1993-08-06 | 2002-11-21 | Epimmune, Inc. | Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl |
-
1994
- 1994-10-19 KR KR1019960701994A patent/KR100235849B1/ko not_active IP Right Cessation
- 1994-10-19 EP EP94930335A patent/EP0728764A4/en not_active Withdrawn
- 1994-10-19 AU AU79487/94A patent/AU685521B2/en not_active Ceased
- 1994-10-19 JP JP51160595A patent/JP3814828B2/ja not_active Expired - Fee Related
- 1994-10-19 CN CN94193851A patent/CN1055701C/zh not_active Expired - Fee Related
- 1994-10-19 WO PCT/JP1994/001756 patent/WO1995011255A1/ja not_active Application Discontinuation
- 1994-10-19 US US08/615,181 patent/US5756666A/en not_active Expired - Lifetime
- 1994-10-19 CA CA002173138A patent/CA2173138A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0728764A4 (en) | 1999-01-20 |
JP3814828B2 (ja) | 2006-08-30 |
KR100235849B1 (ko) | 1999-12-15 |
CA2173138A1 (en) | 1995-04-27 |
CN1055701C (zh) | 2000-08-23 |
CN1133597A (zh) | 1996-10-16 |
EP0728764A1 (en) | 1996-08-28 |
US5756666A (en) | 1998-05-26 |
AU685521B2 (en) | 1998-01-22 |
WO1995011255A1 (fr) | 1995-04-27 |
AU7948794A (en) | 1995-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960704923A (ko) | HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS) | |
Gustafson et al. | Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the CyanobacteriumNostoc ellipsosporum | |
Moon et al. | Glutamate dehydrogenase: amino-acid sequence of the bovine enzyme and comparison with that from chicken liver | |
DE69522216D1 (de) | Zielzellen-bindende chimäre Peptide | |
EP0888122A4 (en) | HYBRID FROM INTERFERON-alpha AND IMMUNGLOBULIN Fc FRAGMENT CONNECTED BY A MIGHTLY IMMUNOGENIC PEPTIDE | |
RU94045919A (ru) | Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция | |
RU98120519A (ru) | Аутоантиген и структурно-родственные ему белки для применения при иммунотерапии аутоиммунных заболеваний | |
KR850002283A (ko) | 동종 면역 인터페론 단편의 제조방법 | |
KR940703860A (ko) | 신규한 사람 쿠니즈형 프로테아제 저해제 및 그의 변이체(a novel human kunitz-type protease inhibitor and variants thereof) | |
DE69310734D1 (de) | Peptid für die stimulierung von für hepatitis c virus spesifischen cytotoischen t lymphozyten | |
Frey et al. | Mechanism of target cell recognition by natural killer cells: characterization of a novel triggering molecule restricted to CD3-large granular lymphocytes. | |
RU98112759A (ru) | Человеческий семафорин l (h-sema-l) и соответствующие семафорины в других видах | |
ABEL et al. | Structural differences in the hinge region of human gamma A myeloma proteins of different subclasses | |
Chatterjee et al. | Homology of adenoviral E3 glycoprotein with HLA-DR heavy chain. | |
KR920012440A (ko) | 인간 인터류킨-5 수용체 | |
GB9311454D0 (en) | Pharmaceutical compositions | |
RU2001127439A (ru) | Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом | |
IL75553A (en) | Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto | |
AU4712993A (en) | New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods | |
KR20090009839A (ko) | 면역조절 올리고펩티드 | |
KR930703444A (ko) | 어류 황체화 호르몬-방출 호르몬 동족체 | |
Basava et al. | Peptides: design, synthesis, and biological activity | |
GB1532169A (en) | Fragments of secretin | |
NZ508812A (en) | Peptides for the prevention or treatment of HIV | |
MX9206732A (es) | Nuevas proteinas inhibidoras de trombina a partir de sanguijuelas de tierra. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090925 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |